Why Science? | ICH Q6A Chemical Substance Specifications and Acceptance Criteria

The guidance addresses specifications for new drug substances and drug products of chemical origin. Higher molecular-weight peptides, many biological products and several specialised categories require other guidance.

The scientific value of q6a defines a chemical-product scope comes from linking knowledge to a defined quality decision. The guidance addresses specifications for new drug substances and drug products of chemical origin. Higher molecular-weight peptides, many biological products and several specialised categories require other guidance. Keep this boundary visible: A specification is not a substitute for process design, validation or GMP.

A strong science note separates observation from interpretation. Trace q6a defines a chemical-product scope to the product risk and decision it controls. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Next chapter

FDA lists Q6A as final ICH guidance for test procedures and acceptance criteria for new chemical drug substances and drug products.

For the december 2000 fda guidance is final, a useful explanation shows both expected performance and the response to variation. FDA lists Q6A as final ICH guidance for test procedures and acceptance criteria for new chemical drug substances and drug products. Preserve this guardrail: Testing every measurable attribute can add noise without improving patient protection.

A strong science note separates observation from interpretation. Challenge the method for the december 2000 fda guidance is final against the closest plausible failure. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Process understanding, material controls, validation, in-process monitoring and GMP support quality. The specification confirms selected attributes; it cannot compensate for an uncontrolled process.

A trustworthy account of a specification is one part of total control keeps evidence, assumptions and lifecycle action together. Process understanding, material controls, validation, in-process monitoring and GMP support quality. The specification confirms selected attributes; it cannot compensate for an uncontrolled process. Remember: A wide limit based only on historical extremes may institutionalise poor process control.

A strong science note separates observation from interpretation. Justify the acceptance criterion for a specification is one part of total control with clinical, batch and stability evidence. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Description, identification, assay and impurities are generally included, with procedures and criteria appropriate to the molecule and process. Additional tests follow product-specific risk.

The scientific value of universal drug-substance tests form a core comes from linking knowledge to a defined quality decision. Description, identification, assay and impurities are generally included, with procedures and criteria appropriate to the molecule and process. Additional tests follow product-specific risk. Keep this boundary visible: Compendial compliance does not remove product-specific tests needed for quality.

A strong science note separates observation from interpretation. Reassess universal drug-substance tests form a core after a process, formulation, method or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Description, identification, assay and impurities are generally considered, along with dosage-form performance and quality tests selected for the product.

For universal drug-product tests address the finished dosage form, a useful explanation shows both expected performance and the response to variation. Description, identification, assay and impurities are generally considered, along with dosage-form performance and quality tests selected for the product. Preserve this guardrail: A specification is not a substitute for process design, validation or GMP.

A strong science note separates observation from interpretation. Trace universal drug-product tests address the finished dosage form to the product risk and decision it controls. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A single nonspecific response may not distinguish the intended substance from a close analogue, salt or mixture. Orthogonal or discriminating identification can be appropriate.

A trustworthy account of identity needs suitable specificity keeps evidence, assumptions and lifecycle action together. A single nonspecific response may not distinguish the intended substance from a close analogue, salt or mixture. Orthogonal or discriminating identification can be appropriate. Remember: Testing every measurable attribute can add noise without improving patient protection.

A strong science note separates observation from interpretation. Challenge the method for identity needs suitable specificity against the closest plausible failure. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The procedure and limit consider manufacturing variability, analytical uncertainty and clinical formulation. Mass balance with impurities can help interpret unexpected results.

The scientific value of assay criteria reflect content and performance comes from linking knowledge to a defined quality decision. The procedure and limit consider manufacturing variability, analytical uncertainty and clinical formulation. Mass balance with impurities can help interpret unexpected results. Keep this boundary visible: A wide limit based only on historical extremes may institutionalise poor process control.

A strong science note separates observation from interpretation. Justify the acceptance criterion for assay criteria reflect content and performance with clinical, batch and stability evidence. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Organic impurities, degradation products, residual solvents and elemental impurities follow their specialised frameworks. Limits should remain consistent with qualified exposure and process capability.

For impurity criteria connect to q3 guidance, a useful explanation shows both expected performance and the response to variation. Organic impurities, degradation products, residual solvents and elemental impurities follow their specialised frameworks. Limits should remain consistent with qualified exposure and process capability. Preserve this guardrail: Compendial compliance does not remove product-specific tests needed for quality.

A strong science note separates observation from interpretation. Reassess impurity criteria connect to q3 guidance after a process, formulation, method or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Polymorph, solvate, hydrate or amorphous content may influence solubility, stability or manufacture. Q6A decision trees help determine whether testing and control are needed.

A trustworthy account of solid-state form can matter when it affects performance keeps evidence, assumptions and lifecycle action together. Polymorph, solvate, hydrate or amorphous content may influence solubility, stability or manufacture. Q6A decision trees help determine whether testing and control are needed. Remember: A specification is not a substitute for process design, validation or GMP.

A strong science note separates observation from interpretation. Trace solid-state form can matter when it affects performance to the product risk and decision it controls. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Size distribution may affect dissolution, bioavailability, blend uniformity, suspension behaviour or processing. A test is justified when these links matter and are not reliably controlled elsewhere.

The scientific value of particle size can become a specification attribute comes from linking knowledge to a defined quality decision. Size distribution may affect dissolution, bioavailability, blend uniformity, suspension behaviour or processing. A test is justified when these links matter and are not reliably controlled elsewhere. Keep this boundary visible: Testing every measurable attribute can add noise without improving patient protection.

A strong science note separates observation from interpretation. Challenge the method for particle size can become a specification attribute against the closest plausible failure. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Immediate, modified-release and other oral products need procedures that can detect relevant formulation or process changes. Media, apparatus, agitation and sampling should be scientifically selected.

For dissolution connects dosage form to release behaviour, a useful explanation shows both expected performance and the response to variation. Immediate, modified-release and other oral products need procedures that can detect relevant formulation or process changes. Media, apparatus, agitation and sampling should be scientifically selected. Preserve this guardrail: A wide limit based only on historical extremes may institutionalise poor process control.

A strong science note separates observation from interpretation. Justify the acceptance criterion for dissolution connects dosage form to release behaviour with clinical, batch and stability evidence. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

For rapidly dissolving immediate-release products with highly soluble drug, disintegration can sometimes serve as the performance test when the scientific conditions and evidence support it.

A trustworthy account of disintegration may substitute only in suitable cases keeps evidence, assumptions and lifecycle action together. For rapidly dissolving immediate-release products with highly soluble drug, disintegration can sometimes serve as the performance test when the scientific conditions and evidence support it. Remember: Compendial compliance does not remove product-specific tests needed for quality.

A strong science note separates observation from interpretation. Reassess disintegration may substitute only in suitable cases after a process, formulation, method or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Moisture can affect degradation or performance, while microbial limits depend on dosage form, route and manufacturing controls. Testing strategy should reflect actual vulnerability.

The scientific value of water and microbial tests follow product risk comes from linking knowledge to a defined quality decision. Moisture can affect degradation or performance, while microbial limits depend on dosage form, route and manufacturing controls. Testing strategy should reflect actual vulnerability. Keep this boundary visible: A specification is not a substitute for process design, validation or GMP.

A strong science note separates observation from interpretation. Trace water and microbial tests follow product risk to the product risk and decision it controls. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

A tighter release limit can provide room for expected change during storage while ensuring the product remains within the shelf-life specification through expiry.

For release and shelf-life criteria can differ, a useful explanation shows both expected performance and the response to variation. A tighter release limit can provide room for expected change during storage while ensuring the product remains within the shelf-life specification through expiry. Preserve this guardrail: Testing every measurable attribute can add noise without improving patient protection.

A strong science note separates observation from interpretation. Challenge the method for release and shelf-life criteria can differ against the closest plausible failure. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Q6A appendices guide choices on attributes such as polymorphism, particle size and dissolution. The applicant still supplies product-specific evidence and rationale.

A trustworthy account of decision trees organise reasoning without replacing judgment keeps evidence, assumptions and lifecycle action together. Q6A appendices guide choices on attributes such as polymorphism, particle size and dissolution. The applicant still supplies product-specific evidence and rationale. Remember: A wide limit based only on historical extremes may institutionalise poor process control.

A strong science note separates observation from interpretation. Justify the acceptance criterion for decision trees organise reasoning without replacing judgment with clinical, batch and stability evidence. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

Reduced frequency may be acceptable for selected attributes when development, validation and manufacturing experience show consistent control. Failures and changes trigger reassessment.

The scientific value of periodic or skip testing requires justified control comes from linking knowledge to a defined quality decision. Reduced frequency may be acceptable for selected attributes when development, validation and manufacturing experience show consistent control. Failures and changes trigger reassessment. Keep this boundary visible: Compendial compliance does not remove product-specific tests needed for quality.

A strong science note separates observation from interpretation. Reassess periodic or skip testing requires justified control after a process, formulation, method or package change. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter · Next chapter

The record includes product knowledge, quality attributes, test purpose, analytical procedure, acceptance criterion, batch and stability data, process capability, clinical relevance, decision-tree rationale, release versus shelf-life logic and change triggers. It makes the specification defensible.

For a complete q6a receipt explains every test and limit, a useful explanation shows both expected performance and the response to variation. The record includes product knowledge, quality attributes, test purpose, analytical procedure, acceptance criterion, batch and stability data, process capability, clinical relevance, decision-tree rationale, release versus shelf-life logic and change triggers. It makes the specification defensible. Preserve this guardrail: A specification is not a substitute for process design, validation or GMP.

A strong science note separates observation from interpretation. Trace a complete q6a receipt explains every test and limit to the product risk and decision it controls. Record the source, version or date, population or device context, method, result and one uncertainty. If the official record does not show a field, write “not shown” instead of filling the gap from memory.

Contents · Previous chapter